Clinical Trial Update: Investigation of Cognitive Outcomes With Cannabidiol Oral Solution [Phase 4]

View source ↗

Summary

Phase 4 investigation of cannabidiol oral solution for cognitive outcomes in Lennox-Gastaut Syndrome was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lennox-gastaut Syndrome

Drugs mentioned

• Cannabidiol Oral Solution (cannabidiol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Lennox-Gastaut Syndrome | Phase 4 | Status: WITHDRAWN